Do PAREXEL International Corporation(NASDAQ:PRXL) and Amsurg Corp(NASDAQ:AMSG) Still Qualify As “Safe” Investments?

0

Atlanta, GA – Scibility Media – 11/06/2014.

This article discusses two companies: PAREXEL International Corporation(NASDAQ:PRXL) and Amsurg Corp(NASDAQ:AMSG)

PAREXEL International Corporation(NASDAQ:PRXL) announced its first quarter fiscal 2015 financial results on Oct. 29th, 2014. The figures included a consolidated service revenue figure of $491.7 million, a 9.4% increase from the $449.2 million figure recorded during the same period of the previous fiscal year. Additionally, PAREXEL also reported a GAAP income of $53.6 million for the period.

On Nov. 4th, the company announced that it would be presenting at the Credit Suisse Healthcare Conference in Phoenix, Arizona. On Nov. 11th, 2014, Ingo Bank, PAREXEL International’s Senior Vice President and Chief Financial Officer, will discuss the company’s business developments at the event. The company has a market capitalization of over $3 billion and 55.02 million tradeable shares.

Starved For Yield? Find New Companies To Invest In!

Amsurg Corp(NASDAQ:AMSG) reported its third quarter financial results on Nov. 4th, 2014. The figures included a net revenue of $503.2 million, a 91.3% increase from the same period during the previous fiscal year. Additionally, AmSurg also reported a net loss from continuing operations of $12.1 million for the period.

The Tennessee-base company acquires and develops ambulatory surgery centers in the United States. AmSurg’s facilities perform colonoscopy and other endoscopy procedures. The company has traded within a range of $40.00 to $54.48 over the past 52 weeks. Given the fact that AmSurg finished its Nov. 5th trading at a closing price of $51.37, it’s safe to say that the company is currently trending upward.

Breaking News Are Important, But Real-Time Communications Are Even Better. Talk To Amsurg Corp Now!

About EquiPress.com

EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.

Sign-up for free now to experience the full benefits of EquiPress pre-launch.

Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.

Can’t find your company on EquiPress? Send us an email to support@equipress.com and we will contact them for you.

Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.

Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.

Share.

Leave A Reply